3 key risk factors for patient-to-patient transmission of resistant bacteria

Researchers have identified three key factors that increase the risk for patients to pass on carbapenemase-producing carbapenem-resistant Enterobacteriacecae to another patient, helping explain why some contacts get the bacteria but others do not.

Advertisement

“The spread of CP-CRE is a major public health concern because it is extremely drug resistant; however, the research on these pathogens is very limited, and so is our knowledge of their transmission,” said Vered Schechner, MD, lead author of the study published in Infection Control & Hospital Epidemiology. “Identifying high-risk groups helps us to avoid excessive screening that can be risky and expensive, and to determine who should be screened and who might be a candidate for pre-emptive isolation or antibiotics.”

Dr. Schechner and the team discovered that 96 percent of patient-to-patient transmission of CP-CRE had at least one of the following three risk factors:

  • Contact for more than three days with an infected person
  • Mechanical ventilation
  • Infection with another multidrug-resistant bacteria

They also discovered patients who take cephalosporins were less likely to acquire CP-CRE than patients who took other types of antibiotics.

More articles on antibiotic resistance:
Antibiotic-resistant bacteria found in Florida wastewater following sewage spill
Despite major concerns about resistance, experts call on UN to widen global antibiotics access
Algorithm predicts effective treatments for drug-resistant fungal infections

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Advertisement

Next Up in Clinical Leadership & Infection Control

Advertisement

Comments are closed.